Barclays Issues Positive Forecast for West Pharmaceutical Services (NYSE:WST) Stock Price

West Pharmaceutical Services (NYSE:WST) had its target price increased by equities research analysts at Barclays from $440.00 to $500.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the medical instruments supplier’s stock. Barclays‘s target price indicates a potential upside of 22.31% from the company’s previous close.

A number of other equities research analysts also recently issued reports on WST. UBS Group increased their price objective on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Morgan Stanley upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $365.00 to $400.00 in a research report on Tuesday, September 22nd. Citigroup lifted their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price objective for the company. Finally, Wall Street Zen cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $396.17.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock traded down $7.89 during mid-day trading on Friday, reaching $408.78. 252,677 shares of the company were exchanged, compared to its average volume of 805,160. The company has a fifty day simple moving average of $366.60 and a 200-day simple moving average of $312.50. West Pharmaceutical Services has a 12 month low of $223.83 and a 12 month high of $438.27. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market cap of $28.77 billion, a PE ratio of 52.51, a PEG ratio of 2.83 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.20 by $0.46. The company had revenue of $874.50 million for the quarter, compared to analysts’ expectations of $827.12 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. West Pharmaceutical Services’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $1.96 earnings per share. As a group, equities research analysts expect that West Pharmaceutical Services will post 8.92 earnings per share for the current fiscal year.

Insider Transactions at West Pharmaceutical Services

In related news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the completion of the transaction, the vice president directly owned 16,845 shares in the company, valued at $5,740,944.45. This represents a 32.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have sold 15,659 shares of company stock worth $5,443,749. 0.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Cornerstone Planning Group LLC boosted its holdings in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 50 shares in the last quarter. Avalon Trust Co bought a new position in West Pharmaceutical Services in the second quarter valued at about $28,000. Addison Advisors LLC bought a new position in West Pharmaceutical Services in the second quarter valued at about $28,000. Raiffeisen Bank International AG boosted its stake in shares of West Pharmaceutical Services by 95.6% during the second quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 65 shares in the last quarter. Finally, Elevation Wealth Partners LLC grew its holdings in shares of West Pharmaceutical Services by 1,377.8% during the second quarter. Elevation Wealth Partners LLC now owns 133 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 124 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, ahead of the $2.18-$2.20 analyst consensus, while revenue reached $874.5 million versus expectations of approximately $827 million. Revenue increased 8.7% year over year, and earnings rose from $1.96 per share in the prior-year quarter. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Full-year guidance was raised: Management now expects 2026 net sales of $3.41 billion to $3.42 billion, up from $3.345 billion to $3.380 billion previously. Adjusted diluted EPS guidance increased to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: High-value products led growth: High-Value Product Components sales rose 19.7% and represented 53% of quarterly sales. The mix shift supported margin expansion and reinforced investor confidence in demand for West’s pharmaceutical packaging and delivery components. West Pharma Q3 Earnings Rise on HVP Strength

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.